SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Aadi Bioscience, Inc. – ‘8-K’ for 8/26/21 – ‘EX-3.1’

On:  Thursday, 8/26/21, at 9:36pm ET   ·   As of:  8/27/21   ·   For:  8/26/21   ·   Accession #:  1193125-21-257910   ·   File #:  1-38560

Previous ‘8-K’:  ‘8-K’ on 8/23/21 for 8/17/21   ·   Next:  ‘8-K’ on 9/3/21 for 8/30/21   ·   Latest:  ‘8-K’ on / for 5/8/24   ·   21 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/27/21  Aadi Bioscience, Inc.             8-K:1,2,3,5 8/26/21   26:11M                                    Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     86K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML     29K 
 3: EX-3.2      Articles of Incorporation/Organization or Bylaws    HTML    122K 
 4: EX-10.1     Material Contract                                   HTML     94K 
12: EX-10.10    Material Contract                                   HTML     58K 
13: EX-10.11    Material Contract                                   HTML     65K 
 5: EX-10.3     Material Contract                                   HTML     76K 
 6: EX-10.4     Material Contract                                   HTML     53K 
 7: EX-10.5     Material Contract                                   HTML     43K 
 8: EX-10.6     Material Contract                                   HTML     79K 
 9: EX-10.7     Material Contract                                   HTML     50K 
10: EX-10.8     Material Contract                                   HTML     77K 
11: EX-10.9     Material Contract                                   HTML     68K 
14: EX-14.1     Code of Ethics                                      HTML     47K 
15: EX-99.1     Miscellaneous Exhibit                               HTML     74K 
16: EX-99.2     Miscellaneous Exhibit                               HTML     25K 
22: R1          Document and Entity Information                     HTML     59K 
24: XML         IDEA XML File -- Filing Summary                      XML     18K 
21: XML         XBRL Instance -- d119681d8k_htm                      XML     20K 
23: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
18: EX-101.DEF  XBRL Definitions -- aadi-20210826_def                XML     46K 
19: EX-101.LAB  XBRL Labels -- aadi-20210826_lab                     XML     74K 
20: EX-101.PRE  XBRL Presentations -- aadi-20210826_pre              XML     47K 
17: EX-101.SCH  XBRL Schema -- aadi-20210826                         XSD     15K 
25: JSON        XBRL Instance as JSON Data -- MetaLinks               15±    25K 
26: ZIP         XBRL Zipped Folder -- 0001193125-21-257910-xbrl      Zip    241K 


‘EX-3.1’   —   Articles of Incorporation/Organization or Bylaws


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-3.1  

Exhibit 3.1

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

AERPIO PHARMACEUTICALS, INC.

a Delaware corporation

Aerpio Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows:

A. The original Certificate of Incorporation of the Company, under the original name “ZETA ACQUISITION CORP. II”, was filed with the Secretary of State of the State of Delaware on November 16, 2007.

B. This Amended and Restated Certificate of Incorporation was duly adopted in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware (the “DGCL”) by the Board of Directors of the Company (the “Board of Directors”) and the affirmative vote of the stockholders of the Company.

C. The text of the Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety to read as follows:

ARTICLE I

The name of the Company is Aadi Bioscience, Inc.

ARTICLE II

The address of the Company’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801. The name of the registered agent at such address is The Corporation Trust Company.

ARTICLE III

The nature of the business or purposes to be conducted or promoted by the Company is to engage in any lawful act or activity for which corporations may be organized under the DGCL.

ARTICLE IV

Section 1. This Company is authorized to issue two classes of stock, to be designated, respectively, Common Stock and Preferred Stock. The total number of shares of stock that the Company shall have authority to issue is 310,000,000 shares, of which 300,000,000 shares are Common Stock, $0.0001 par value per share (the “Common Stock”), and 10,000,000 shares are Preferred Stock, $0.0001 par value per share (the “Preferred Stock”).

That, as of the effectiveness of the filing of this Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Effective Time”), each fifteen (the “Conversion Number”) shares of the Common Stock issued and outstanding or held in treasury as of the Effective Time shall be combined into one validly issued, fully paid and non-assessable share of Common Stock, automatically and without any action by the holder thereof (the “Reverse Stock Split”). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.0001 per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split. In lieu of any fractional


shares to which a stockholder would otherwise be entitled (after taking into account all fractional shares of Common Stock otherwise issuable to such holder), the Company shall, upon surrender of such holder’s certificate(s) representing such fractional shares of Common Stock (if any), pay cash in an amount equal to such fractional shares of Common Stock multiplied by the then fair value of the Common Stock as determined by the Board of Directors.

Each stock certificate or book entry share that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such certificate or book entry share have been combined (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time); provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined.

Section 2. Except as otherwise provided herein, each share of Common Stock outstanding as of the applicable record date shall entitle the holder thereof to one (1) vote on any matter submitted to a vote at a meeting of stockholders.

Section 3. The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any series of Preferred Stock, including, without limitation, authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing. The Board of Directors is further authorized to increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series, subject to the powers, preferences and rights, and the qualifications, limitations and restrictions thereof stated in this Amended and Restated Certificate of Incorporation or the resolution of the Board of Directors originally fixing the number of shares of such series. Except as may be otherwise specified by the terms of any series of Preferred Stock, if the number of shares of any series of Preferred Stock is so decreased, then the Company shall take all such steps as are necessary to cause the shares constituting such decrease to resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series.

Section 4. Except as otherwise required by law or provided in this Amended and Restated Certificate of Incorporation, holders of Common Stock shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock).

 

- 2 -


Section 5. The number of authorized shares of Preferred Stock or Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of all the then-outstanding shares of capital stock of the Company entitled to vote thereon, without a separate vote of the holders of the class or classes the number of authorized shares of which are being increased or decreased, unless a vote of any holders of one or more series of Preferred Stock is required pursuant to the terms of any certificate of designation relating to any series of Preferred Stock, irrespective of the provisions of Section 242(b)(2) of the DGCL.

ARTICLE V

Section 1. Subject to the rights of holders of Preferred Stock, the number of directors that constitutes the entire Board of Directors shall be fixed only by resolution of the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board. For the purposes of this Amended and Restated Certificate of Incorporation, the term “Whole Board” shall mean the total number of authorized directorships whether or not there exist any vacancies or other unfilled seats in previously authorized directorships. At each annual meeting of stockholders, directors of the Company shall be elected to hold office until the expiration of the term for which they are elected and until their successors have been duly elected and qualified or until their earlier resignation, death or removal; except that if any such meeting shall not be so held, such election shall take place at a stockholders’ meeting called and held in accordance with the DGCL.

Section 2. The directors of the Company (other than any who may be elected by holders of Preferred Stock under specified circumstances) are divided into three classes as nearly equal in size as is practicable, designated Class I, Class II and Class III. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. If the number of directors is changed, any newly created directorships or decrease in directorships shall be so apportioned hereafter among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

ARTICLE VI

Section 1. From and after the effectiveness of this Amended and Restated Certificate of Incorporation, only for so long as the Board of Directors is classified and subject to the rights of holders of Preferred Stock, any director or the entire Board of Directors may be removed from office at any time, but only for cause, and only by the affirmative vote of the holders of at least a majority of the voting power of the issued and outstanding capital stock of the Company entitled to vote in the election of directors.

Section 2. Except as otherwise provided for or fixed by or pursuant to the provisions of ARTICLE IV hereof in relation to the rights of the holders of Preferred Stock to elect directors under specified circumstances or except as otherwise provided by resolution of a majority of the Whole Board, newly created directorships resulting from any increase in the number of directors, created in accordance with the Bylaws of the Company, and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause shall be filled only by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders. A person so elected by the Board of Directors to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall have been chosen and until his or her successor shall have been duly elected and qualified, or until such director’s earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

 

- 3 -


ARTICLE VII

Section 1. The Company is to have perpetual existence.

Section 2. The business and affairs of the Company shall be managed by or under the direction of the Board of Directors. In addition to the powers and authority expressly conferred upon them by statute or by this Amended and Restated Certificate of Incorporation or the Bylaws of the Company, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Company.

Section 3. In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, alter, amend or repeal the Bylaws of the Company. The affirmative vote of at least a majority of the Whole Board shall be required in order for the Board of Directors to adopt, amend, alter or repeal the Company’s Bylaws. The Company’s Bylaws may also be adopted, amended, altered or repealed by the stockholders of the Company. Notwithstanding the above or any other provision of this Amended and Restated Certificate of Incorporation, the Bylaws of the Company may not be amended, altered or repealed by the stockholders of the Company except in accordance with the provisions of the Bylaws relating to amendments to the Bylaws. No Bylaw hereafter legally adopted, amended, altered or repealed shall invalidate any prior act of the directors or officers of the Company that would have been valid if such Bylaw had not been adopted, amended, altered or repealed.

Section 4. The election of directors need not be by written ballot unless the Bylaws of the Company shall so provide.

Section 5. No stockholder will be permitted to cumulate votes at any election of directors.

ARTICLE VIII

Section 1. Subject to the rights of holders of Preferred Stock, any action required or permitted to be taken by the stockholders of the Company must be effected at a duly called annual or special meeting of stockholders of the Company and may not be effected by any consent in writing by such stockholders.

Section 2. Subject to the terms of any series of Preferred Stock, special meetings of stockholders of the Company may be called only by the chairperson of the Board of Directors, the chief executive officer, the president or the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board, but a special meeting may not be called by any other person or persons and any power of stockholders to call a special meeting of stockholders is specifically denied. Only such business shall be considered at a special meeting of stockholders as shall have been stated in the notice for such meeting.

Section 3. Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Company shall be given in the manner and to the extent provided in the Bylaws of the Company.

ARTICLE IX

Section 1. To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended from time to time, a director of the Company shall not be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

 

- 4 -


Section 2. Subject to any provisions in the Bylaws of the Company related to indemnification of directors of the Company, the Company shall indemnify, to the fullest extent permitted by applicable law, any director of the Company who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”) by reason of the fact that he or she is or was a director of the Company or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. The Company shall be required to indemnify a person in connection with a Proceeding (or part thereof) initiated by such person only if the Proceeding (or part thereof) was authorized by the Board of Directors.

Section 3. The Company shall have the power to indemnify, to the extent permitted by applicable law, any officer, employee or agent of the Company who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of the Company or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding.

Section 4. Neither any amendment, repeal, nor elimination of any Section of this ARTICLE IX, nor the adoption of any provision of this Amended and Restated Certificate of Incorporation or the Bylaws of the Company inconsistent with this ARTICLE IX, shall eliminate or reduce the effect of this ARTICLE IX in respect of any matter occurring, or any Proceeding accruing or arising or that, but for this ARTICLE IX, would accrue or arise, prior to such amendment, repeal, elimination or adoption of an inconsistent provision.

ARTICLE X

Meetings of stockholders may be held within or outside of the State of Delaware, as the Bylaws may provide. The books of the Company may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws of the Company.

The Company reserves the right to amend or repeal any provision contained in this Amended and Restated Certificate of Incorporation in the manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation.

 

- 5 -


IN WITNESS WHEREOF, the Company has caused this Amended and Restated Certificate of Incorporation to be signed by its President on this 26th day of August 2021.

 

By:  

/s/ Joseph Gardner

  Joseph Gardner
  President

 

- 6 -


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed as of:8/27/214
Filed on / For Period end:8/26/213,  4,  4/A,  8-K/A
11/16/07
 List all Filings 


20 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/08/24  Aadi Bioscience, Inc.             10-Q        3/31/24   69:6.6M                                   Workiva Inc Wde… FA01/FA
 3/13/24  Aadi Bioscience, Inc.             10-K       12/31/23   81:12M                                    Workiva Inc Wde… FA01/FA
 2/12/24  Aadi Bioscience, Inc.             S-8         2/12/24    4:95K                                    Donnelley … Solutions/FA
 2/12/24  Aadi Bioscience, Inc.             S-3                    4:622K                                   Donnelley … Solutions/FA
11/08/23  Aadi Bioscience, Inc.             10-Q        9/30/23   69:6.9M                                   Workiva Inc Wde… FA01/FA
 8/09/23  Aadi Bioscience, Inc.             10-Q        6/30/23   68:6.7M                                   Workiva Inc Wde… FA01/FA
 5/10/23  Aadi Bioscience, Inc.             10-Q        3/31/23   67:6.7M                                   Workiva Inc Wde… FA01/FA
 3/29/23  Aadi Bioscience, Inc.             10-K       12/31/22   92:31M                                    Workiva Inc Wde… FA01/FA
 3/29/23  Aadi Bioscience, Inc.             S-8         3/29/23    4:87K                                    Donnelley … Solutions/FA
 1/17/23  Desai Neil                        SC 13D/A               1:50K  Aadi Bioscience, Inc.             Donnelley … Solutions/FA
11/09/22  Aadi Bioscience, Inc.             10-Q        9/30/22   72:7.5M                                   Workiva Inc Wde… FA01/FA
 8/10/22  Aadi Bioscience, Inc.             10-Q        6/30/22   64:6.3M                                   Workiva Inc Wde… FA01/FA
 5/12/22  Aadi Bioscience, Inc.             10-Q        3/31/22   64:9.5M                                   ActiveDisclosure/FA
 3/17/22  Aadi Bioscience, Inc.             10-K       12/31/21   84:13M                                    ActiveDisclosure/FA
 3/17/22  Aadi Bioscience, Inc.             S-8         3/17/22    4:76K                                    Donnelley … Solutions/FA
11/10/21  Aadi Bioscience, Inc.             10-Q        9/30/21   76:12M                                    ActiveDisclosure/FA
10/04/21  Aadi Bioscience, Inc.             424B3      10/01/21    1:241K                                   Donnelley … Solutions/FA
 9/24/21  Aadi Bioscience, Inc.             S-8         9/24/21    4:95K                                    Donnelley … Solutions/FA
 9/24/21  Aadi Bioscience, Inc.             S-3                    4:333K                                   Donnelley … Solutions/FA
 9/07/21  Acuta Capital Partners, LLC       SC 13D                 1:66K  Aadi Bioscience, Inc.             Toppan Merrill/FA


1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/17/21  Aadi Bioscience, Inc.             8-K:1,3,5,7 5/16/21    5:1.3M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001193125-21-257910   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 3:11:44.3pm ET